Market Overview

UPDATE: Auriga Downgrades Anthera Pharmaceuticals


According to a research report released earlier today, Auriga has downgraded Anthera Pharmaceuticals Inc. (NASDAQ: ANTH) from Hold to Sell based on excessive valuation.

Auriga commented in the report, “We also note interesting competition from upstart CareCloud (private) which boasts a more flexible approach to the revenue cycle and a much friendlier and intuitive user interface. Given the stock's 50% move since its Analyst Day in December, on what we perceive to be weakening fundamentals, we recommend investors take profits as we envision 25% downside from current levels. Our $57 price target is unchanged.”

Anthera Pharmaceuticals closed yesterday at $75.65.

Posted-In: AurigaAnalyst Color Downgrades Analyst Ratings


Related Articles (ANTH)

View Comments and Join the Discussion!

Latest Ratings

WUBABOCOM InternationalDowngrades
DLTROTR GlobalUpgrades
ARCCCompass PointDowngrades
GTYHCitiInitiates Coverage On7.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

European morning wrap: Japanese yen claws back a little lost ground

Bluebird Energy Posts Narrower H1 Loss